BRAINLIFE.ORG




Current Neuro-Oncology




Volume 25 Number 10
31 May 2023




Home > Publications > Current Neuro-Oncology > Volume 25, Year 2023 > Number 10, 31 May






Maseko R, Mabogo M, Lockhat Z, Makunyane P, Ahmad S, Bida M, Padayachy L.
Transorbital neuroendoscopy-assisted resection of a giant optic pathway glioma in a neonate.
Childs Nerv Syst. 2023 May 16
. doi: 10.1007/s00381-023-05986-1. PMID: 37191728. Case report. ˍ




Movahed-Ezazi M, Nasir-Moin M, Fang C, Pizzillo I, Galbraith K, Drexler S, Krasnozhen-Ratush OA, Shroff S, Zagzag D, William C, Orringer D, Snuderl M.
Clinical Validation of Stimulated Raman Histology for Rapid Intraoperative Diagnosis of CNS Tumors.
Mod Pathol. 2023 May 16:100219
. doi: 10.1016/j.modpat.2023.100219. PMID: 37201685. Observational study˰ ˍ




Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD.
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
Cancer Res. 2023 May 17:OF1-OF17
. doi: 10.1158/0008-5472.CAN-23-0186. PMID: 37195023. Interventional study protocol. ˍ




Pouessel D, Ken S, Gouaze-Andersson V, Piram L, Mervoyer A, Larrieu-Ciron D, Cabarrou B, Lusque A, Robert M, Frenel JS, Uro-Coste E, Olivier P, Mounier M, Sabatini U, Sanchez EH, Zouitine M, Berjaoui A, Cohen-Jonathan Moyal E.
Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results.
Oncologist. 2023 May 17:oyad095
. doi: 10.1093/oncolo/oyad095. PMID: 37196069. Interventional study. ˍ




Dentel A, Bremond-Gignac D, Robert MP.
Intravitreal Glioma in a Boy Aged 7 Years.
JAMA Ophthalmol. 2023 May 18;141(5):e230083
. doi: 10.1001/jamaophthalmol.2023.0083. PMID: 37199810. Case report˰ ˍ




Kinslow CJ, Mercurio A, Kumar P, Rae AI, Siegelin MD, Grinband J, Taparra K, Upadhyayula PS, McKhann GM, Sisti MB, Bruce JN, Canoll PD, Iwamoto FM, Kachnic LA, Yu JB, Cheng SK, Wang TJC.
Association of MGMT Promotor Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
JAMA Oncol. 2023 May 18:e230990
. doi: 10.1001/jamaoncol.2023.0990. PMID: 37200021. Observational study˰ ˍ




Stritzelberger J, Gesmann A, Fuhrmann I, Brandner S, Welte TM, Balk S, Eisenhut F, Dörfler A, Coras R, Adler W, Schwab S, Putz F, Fietkau R, Distel L, Hamer H.
Time dependent risk factors for epileptic seizures in glioblastoma patients: A retrospective analysis of 520 cases.
Epilepsia. 2023 May 18
. doi: 10.1111/epi.17658. PMID: 37203264. Observational study˰ ˍ




Dejonckheere CS, Thelen A, Simon B, Greschus S, Köksal MA, Schmeel LC, Wilhelm-Buchstab T, Leitzen C.
Impact of Postoperative Changes in Brain Anatomy on Target Volume Delineation for High-Grade Glioma.
Cancers (Basel). 2023 May 19;15(10):2840. doi: 10.3390/cancers15102840. PMID: 37345177. Observational study. ˍ




Esparragosa Vazquez I, Ndiaye M, Di Stefano AL, Younan N, Larrieu-Ciron D, Seyve A, Picart T, Meyronet D, Boutet C, Vassal F, Carpentier C, Figarella-Branger D, Dehais C, Forest F, Rivoirard R, Ducray F; POLA network.
FLAIR pseudoprogression in patients with anaplastic oligodendrogliomas treated with PCV chemotherapy alone.
Eur J Neurol. 2023 May 19
. doi: 10.1111/ene.15873. PMID: 37204066. Observational study˰ ˍ




Ortega-Leonard LV, Del Río-Portilla Y.
EEG spectral power during REM sleep in patients with frontal brain tumor.
BMC Neurol. 2023 May 19;23(1):195
. doi: 10.1186/s12883-023-03243-1. PMID: 37208614. Observational study. ˍ




Ye L, Gu L, Zheng Z, Zhang X, Xing H, Guo X, Chen W, Wang Y, Wang Y, Liang T, Wang H, Li Y, Jin S, Shi Y, Liu D, Yang T, Liu Q, Deng C, Wang Y, Ma W.
An online survival predictor in glioma patients using machine learning based on WHO CNS5 data.
Front Neurol. 2023 May 19;14:1179761. doi: 10.3389/fneur.2023.1179761. PMID: 37273702. Observational study. ˍ




Constante M, Domingos J, Neves Coelho F, Baptista Fernandes T, Baptista T, Maio Herculano M.
Strongyloides stercoralis Dissemination and Hyperinfection Associated with Long-Term Steroid Treatment in a Neurosurgical Population.
Case Rep Infect Dis. 2023 May 22;2023:4412935. doi: 10.1155/2023/4412935. PMID: 37261247. Case report. ˍ




Minasi S, Gianno F, Bargiacchi L, Barresi V, Miele E, Antonelli M, Buttarelli FR.
Case report of a pediatric medulloblastoma with concurrent MYC and MYCN subclonal amplification in distinct populations of neoplastic cells.
Virchows Arch. 2023 May 22
. doi: 10.1007/s00428-023-03560-3. PMID: 37212894. Case report˰ ˍ




Alimohamadi M, Pour-Rashidi A, Digaleh H, Ajam Zibadi H, Hendi K, Raminfard S, Rahmani M, Larijani A, Shirani M.
Disparity of primary and secondary language outcomes in bilingual patients undergoing resection of glioma of the speech-related regions.
World Neurosurg. 2023 May 23:S1878-8750(23)00693-9
. doi: 10.1016/j.wneu.2023.05.057. PMID: 37230244. Observational study˰ ˍ




Unnikrishnan S, Karunamuni R, Salans MA, Gudipati S, Qian AS, Yu J, Connor M, Huynh-Le MP, Tibbs MD, Hermann G, Reyes A, Stasenko A, Seibert TM, McDonald C, Hattangadi-Gluth JA.
Dose-dependent atrophy in bilateral amygdalae and nuclei after brain radiotherapy: Association with mood and memory outcomes on a longitudinal clinical trial.
Int J Radiat Oncol Biol Phys. 2023 May 23
. doi: 10.1016/j.ijrobp.2023.05.026. PMID: 37230430. Interventional study˰ ˍ




Wang Y, Fushimi Y, Arakawa Y, Shimizu Y, Sano K, Sakata A, Nakajima S, Okuchi S, Hinoda T, Oshima S, Otani S, Ishimori T, Tanji M, Mineharu Y, Yoshida K, Nakamoto Y.
Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET.
Jpn J Radiol. 2023 May 23
. doi: 10.1007/s11604-023-01450-x. PMID: 37219717. Interventional study. ˍ




An J, Freeman E, Stewart IJ, Dore M.
Association of Traumatic Brain Injury and Glioblastoma Multiforme: A Case Series.
Mil Med. 2023 May 24:usad162
. doi: 10.1093/milmed/usad162. PMID: 37223958. Case report. ˍ




Look T, Puca E, Bühler M, Kirschenbaum D, De Luca R, Stucchi R, Ravazza D, Di Nitto C, Roth P, Katzenelenbogen Y, Weiner A, Rindlisbacher L, Becher B, Amit I, Weller M, Neri D, Hemmerle T, Weiss T.
Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma.
Sci Transl Med. 2023 May 24;15(697):eadf2281
. doi: 10.1126/scitranslmed.adf2281. PMID: 37224228. Laboratory investigation, Interventional study˰ ˍ




Moreno L, Teira P, Croop JM, Gerber NU, André N, Aerts I, Gros Subias L, De Wilde B, Bautista F, Turpin B, Kunduri S, Hamidi A, Lawrence T, Streby KA.
A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors.
Front Pediatr. 2023 May 24;11:1183295. doi: 10.3389/fped.2023.1183295. PMID: 37292376. Interventional study. ˍ



*

Kassubek R, Lulé D, Ludolph AC, Kassubek J, Müller HP.
Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma.
Front Neurol. 2023 May 25;14:1191226. doi: 10.3389/fneur.2023.1191226. PMID: 37305747. Observational study. ˍ




Fareed A, Rohail S, Adnan A, Khan AM.
DCvax: A promising advancement in oncology for the treatment of glioblastoma.
Rare Tumors. 2023 May 26;15:20363613231179541
. doi: 10.1177/20363613231179541. PMID: 37256198. Letter. ˍ
REFERS TO: A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM).
Principal Investigator: Linda Liau, M.D. University of California, Los Angeles.
Study start date: December 2006. Estimated Primary Completion Date: November 2022.
ClinicalTrials.gov Identifier: NCT00045968
.
Liau LM, et al.: Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5370. PMID: 36394838. Interventional study. ˍ




Kazerooni AF, Khalili N, Liu X, Haldar D, Jiang Z, Anwar SM, Albrecht J, Adewole M, Anazodo U, Anderson H, Bagheri S, Baid U, Bergquist T, Calabrese E, Chung V, Conte GM, Dako F, Eddy J, Ezhov I, Familiar A, Farahani K, Haldar S, Iglesias JE, Janas A, Johansen E, Kofler F, LaBella D, Leemput KV, Li HB, Maleki N, Meier Z, Menze B, Moawad AW, Piraud M, Poussaint T, Reitman Z, Rudie JD, Shaikh IS, Shinohara RT, Tu W, Viswanathan K, Wang C, Ware JB, Wiestler B, Wiggins W, Zapaishchykova A, Aboian M, Bornhorst M, de Blank P, Deutsch M, Fouladi M, Hoffman L, Kann B, Lazow M, Mikael L, Nabavizadeh A, Packer R, Resnick A, Rood B, Vossough A, Bakas S, Linguraru MG.
The Brain Tumor Segmentation (BraTS) Challenge 2023: Focus on Pediatrics (CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs).
ArXiv [Preprint]. 2023 May 26:arXiv:2305.17033v1. PMID: 37292481. Observational study. ˍ




Koessinger D, Novo D, Koessinger A, Campos A, Peters J, Dutton L, Paschke P, Zerbst D, Moore M, Mitchell L, Neilson M, Stevenson K, Chalmers A, Tait S, Birch J, Norman J.
Glioblastoma extracellular vesicles influence glial cell hyaluronic acid deposition to promote invasiveness.
Neurooncol Adv. 2023 May 27;5(1):vdad067. doi: 10.1093/noajnl/vdad067. PMID: 37334166. Laboratory investigation. ˍ



*

Kubelt C, Hellmold D, Esser D, Ahmeti H, Synowitz M, Held-Feindt J.
Insights into Gene Regulation under Temozolomide-Promoted Cellular Dormancy and Its Connection to Stemness in Human Glioblastoma.
Cells. 2023 May 27;12(11):1491. doi: 10.3390/cells12111491. PMID: 37296610. Laboratory investigation. ˍ
SEE ALSO: Adamski V, et al., Dormant glioblastoma cells acquire stem cell characteristics and are differentially affected by Temozolomide and AT101 treatment. Oncotarget. 2017 Nov 18;8(64):108064-108078. doi: 10.18632/oncotarget.22514. PMID: 29296224. Laboratory investigation. ˍ




Oraee-Yazdani S, Tavanaei R, Rostami F, Hajarizadeh A, Mehrabadi M, Akhlaghpasand M, Tamaddon M, Khannejad S, Yazdani KO, Zali A.
Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trial.
J Transl Med. 2023 May 27;21(1):350. doi: 10.1186/s12967-023-04213-4. PMID: 37245011. Interventional study. ˍ




Sirirungreung A, Hansen J, Ritz B, Heck JE.
Association between medically diagnosed postnatal infection and childhood cancers: A matched case-control study in Denmark, 1978 to 2016.
Int J Cancer. 2023 May 27
. doi: 10.1002/ijc.34604∟. PMID: 37243370∟. Observational study. ˍ




Ohmura K, Ikegame Y, Yano H, Shinoda J, Iwama T.
Methionine-PET to differentiate between brain lesions appearing similar on conventional CT/MRI scans.
J Neuroimaging. 2023 May 28
. doi: 10.1111/jon.13126. PMID: 37246342. Observational study˰ ˍ




Piedade GS, Manoku E, Gelhardt AL, Cordeiro JG, Terzis JA.
Atypical Presentation of a Hemorrhagic Glioblastoma Multiforme Mimicking a Cerebral Contusion.
Cureus. 2023 May 28;15(5):e39592. doi: 10.7759/cureus.39592. PMID: 37384093. Case report. ˍ




Diaz M, Rana S, Silva Correia CE, Reiner AS, Lin AL, Miller AM, Graham MS, Chudsky S, Bale TA, Rosenblum M, Karajannis MA, Pentsova E.
Leptomeningeal disease in histone-mutant gliomas.
Neurooncol Adv. 2023 May 29;5(1):vdad068. doi: 10.1093/noajnl/vdad068. PMID: 37346983. Observational study. ˍ




Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL.
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.
Int J Cancer. 2023 May 29
. doi: 10.1002/ijc.34569. PMID: 37246577. Interventional study. ˍ




Martucci M, Ferranti AM, Schimperna F, Infante A, Magnani F, Olivi A, D'Alessandris QG, Gessi M, Chiesa S, Mazzarella C, Russo R, Giordano C, Gaudino S.
Magnetic resonance imaging-derived parameters to predict response to regorafenib in recurrent glioblastoma.
Neuroradiology. 2023 May 29. doi: 10.1007/s00234-023-03169-y. PMID: 37247021. Observational study˰ ˍ




McLaughlin LA, Yildirim O, Rosenblum MK, Imber BS, Haseltine JM, Zelefsky MJ, Schöder H, Morris MJ, Rafelson WM, Krebs S, Moss NS.
Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT.
J Neurooncol. 2023 May 29
. doi: 10.1007/s11060-023-04355-x. PMID: 37247180. Observational study˰ ˍ




Zemskova O, Yu NY, Trillenberg P, Bonsanto MM, Leppert J, Rades D.
Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy.
Anticancer Res. 2023 May 29;43(6):2725-2732. doi: 10.21873/anticanres.16439. PMID: 37247904. Observational study. ˍ




Bander ED, Kelly A, Ma X, Christos PJ, Wernicke AG, Stieg PE, Trichter S, Knisely JPS, Ramakrishna R, Schwartz TH.
Safety and efficacy of Cesium-131 brachytherapy for brain tumors.
J Neurooncol. 2023 May 30
. doi: 10.1007/s11060-023-04352-0. PMID: 37249824. Observational study˰ ˍ



*

Guberina N, Padeberg F, Pöttgen C, Guberina M, Lazaridis L, Jabbarli R, Deuschl C, Herrmann K, Blau T, Wrede KH, Keyvani K, Scheffler B, Hense J, Layer JP, Glas M, Sure U, Stuschke M.
Location of Recurrences after Trimodality Treatment for Glioblastoma with Respect to the Delivered Radiation Dose Distribution and Its Influence on Prognosis.
Cancers (Basel). 2023 May 30;15(11):2982. doi: 10.3390/cancers15112982. PMID: 37296942. Observational study. ˍ




Karschnia P, Dono A, Young JS, Juenger ST, Teske N, Häni L, Sciortino T, Mau CY, Bruno F, Nunez L, Morshed RA, Haddad AF, Weller M, van den Bent M, Beck J, Hervey-Jumper S, Molinaro AM, Tandon N, Rudà R, Vogelbaum MA, Bello L, Schnell O, Grau SJ, Chang SM, Berger MS, Esquenazi Y, Tonn JC.
Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
Neuro Oncol. 2023 May 30:noad074. doi: 10.1093/neuonc/noad074. PMID: 37253096. Observational study. ˍ




Asl NS, Behfar M, Amiri RS, Mohseni R, Azimi M, Firouzi J, Faranoush M, Izadpanah A, Mohmmad M, Hamidieh AA, Habibi Z, Ebrahimi M.
Intra-lesion injection of activated Natural Killer (NK) cells in recurrent malignant brain tumors.
Int Immunopharmacol. 2023 May 31;120:110345. doi: 10.1016/j.intimp.2023.110345. PMID: 37267858. Observational study˰ ˍ




Moore-Palhares D, Chen H, Keith J, Wang M, Myrehaug S, Tseng CL, Detsky J, Perry J, Lim-Fat MJ, Heyn C, Maralani P, Lipsman N, Das S, Sahgal A, Soliman H.
Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis.
J Neurooncol. 2023 May 31
. doi: 10.1007/s11060-023-04340-4. PMID: 37256526. Observational study˰ ˍ




Vize CJ, Kim SK, Matthews T, Macsai M, Merrell R, Hsu S, Kundu MG, Yoon J, Kennedy E, Pai M, Bain E, Lassman AB, Moazami G.
A Phase 3b Study for Management of Ocular Side Effects in Patients with EGFR-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin.
Ophthalmic Res. 2023 May 31. doi: 10.1159/000531142? PMID: 37257422. Interventional study. ˍ